"Neuromuscular Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used for their actions on skeletal muscle. Included are agents that act directly on skeletal muscle, those that alter neuromuscular transmission (NEUROMUSCULAR BLOCKING AGENTS), and drugs that act centrally as skeletal muscle relaxants (MUSCLE RELAXANTS, CENTRAL). Drugs used in the treatment of movement disorders are ANTI-DYSKINESIA AGENTS.
| Descriptor ID |
D009465
|
| MeSH Number(s) |
D27.505.696.663.700
|
| Concept/Terms |
Neuromuscular Effect- Neuromuscular Effect
- Effect, Neuromuscular
- Neuromuscular Effects
- Effects, Neuromuscular
|
Below are MeSH descriptors whose meaning is more general than "Neuromuscular Agents".
Below are MeSH descriptors whose meaning is more specific than "Neuromuscular Agents".
This graph shows the total number of publications written about "Neuromuscular Agents" by people in this website by year, and whether "Neuromuscular Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 2 | 0 | 2 |
| 1999 | 1 | 1 | 2 |
| 2000 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 2 | 2 | 4 |
| 2004 | 6 | 0 | 6 |
| 2005 | 3 | 1 | 4 |
| 2006 | 5 | 1 | 6 |
| 2007 | 1 | 1 | 2 |
| 2008 | 2 | 0 | 2 |
| 2009 | 4 | 2 | 6 |
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 0 | 2 |
| 2012 | 2 | 4 | 6 |
| 2013 | 2 | 1 | 3 |
| 2014 | 3 | 0 | 3 |
| 2015 | 0 | 1 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 2 | 2 | 4 |
| 2018 | 5 | 1 | 6 |
| 2019 | 2 | 0 | 2 |
| 2020 | 2 | 1 | 3 |
| 2021 | 4 | 0 | 4 |
| 2022 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neuromuscular Agents" by people in Profiles.
-
Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled Trial. Neurology. 2024 02 27; 102(4):e208091.
-
Neutralizing Antibody Formation with OnabotulinumtoxinA (BOTOX?) Treatment from Global Registration Studies across Multiple Indications: A Meta-Analysis. Toxins (Basel). 2023 05 17; 15(5).
-
Drooling and Aspiration of Saliva. Otolaryngol Clin North Am. 2022 Dec; 55(6):1181-1194.
-
Prospective Evaluation of Intradetrusor Injections of OnabotulinumtoxinA in Adults With Spinal Dysraphism. Urology. 2022 Mar; 161:146-152.
-
Duration and onset of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-na?ve subjects. Curr Med Res Opin. 2021 10; 37(10):1761-1768.
-
Long-term efficacy and safety of botulinum toxin treatment for cervical dystonia: a critical reappraisal. Expert Opin Drug Saf. 2021 Jun; 20(6):695-705.
-
Real-world analysis of botulinum toxin (BoNT) injections in post-stroke spasticity: Higher doses of BoNT and longer intervals in the early-start group. J Neurol Sci. 2021 06 15; 425:117449.
-
Efficacy of Botulinum Toxin in Treating Lateral Epicondylitis-Does Injection Location Matter?: A Systematic Review. Am J Phys Med Rehabil. 2020 12; 99(12):1157-1163.
-
Effective Treatment of Geniospasm: Case Series and Review of the Literature. Tremor Other Hyperkinet Mov (N Y). 2020 08 17; 10:31.
-
Treatment of Tardive Dyskinesia. Neurol Clin. 2020 05; 38(2):379-396.